According to the Canadian Consensus Practice Guidelines on tumour biomarker testing for mCRC, the minimum biomarker testing required across all Canadian jurisdictions for mCRC patients requires testing for KRAS/NRAS, BRAF, and MMR/MSI prior to the initiation of 1L therapy [33]. This evidence concerns the gene KRAS and neoplasm.